APA

Antonarakis E. S., Heath E. I., Posadas E. M., Yu E. Y., Harrison M. R., Bruce J. Y., Cho S. Y., Wilding G. E., Fetterly G. J., Hangauer D. G., Kwan M. R., Dyster L. M. & Carducci M. A. (20130613). A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. : Cancer chemotherapy and pharmacology.

Chicago

Antonarakis Emmanuel S, Heath Elisabeth I, Posadas Edwin M, Yu Evan Y, Harrison Michael R, Bruce Justine Y, Cho Steve Y, Wilding Gregory E, Fetterly Gerald J, Hangauer David G, Kwan Min-Fun R, Dyster Lyn M and Carducci Michael A. 20130613. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. : Cancer chemotherapy and pharmacology.

Harvard

Antonarakis E. S., Heath E. I., Posadas E. M., Yu E. Y., Harrison M. R., Bruce J. Y., Cho S. Y., Wilding G. E., Fetterly G. J., Hangauer D. G., Kwan M. R., Dyster L. M. and Carducci M. A. (20130613). A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. : Cancer chemotherapy and pharmacology.

MLA

Antonarakis Emmanuel S, Heath Elisabeth I, Posadas Edwin M, Yu Evan Y, Harrison Michael R, Bruce Justine Y, Cho Steve Y, Wilding Gregory E, Fetterly Gerald J, Hangauer David G, Kwan Min-Fun R, Dyster Lyn M and Carducci Michael A. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. : Cancer chemotherapy and pharmacology. 20130613.